British Thoracic Oncology Group (BTOG) Annual Report - April 2014 to March 2015

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "British Thoracic Oncology Group (BTOG) Annual Report - April 2014 to March 2015"

Transcription

1 British Thoracic Oncology Group (BTOG) Annual Report - April 2014 to March 2015 BTOG s Aim BTOG is the multi-disciplinary group for professionals involved with thoracic malignancies. BTOG aims to improve the care of patients with thoracic malignancies through multidisciplinary education, developing and advising on guidelines for patient care and facilitating and nurturing clinical trial ideas into full protocols. The organisation now has a membership/e-circulation list of over 2,000 thoracic oncology health care professionals. BTOG members are from all professions involved in the care of lung cancer and mesothelioma throughout the UK and Ireland including medical and clinical oncologists, surgeons, radiotherapists, radiologists, nurses (specialist, research/trials, chemotherapy and academic), pharmacists and scientists. BTOG are a not for profit organisation which is kindly hosted by University Hospitals of Leicester NHS Trust (UHL) and the secretariat is based at Glenfield Hospital in Leicester. BTOG does not receive any funding from UHL or the NHS and at present receives financial support through sponsorship and educational grants from industry. BTOG Chair Professor Ken O Byrne formerly from St James s Hospital, Dublin and now Professor of Medical Oncology, Faculty of Health at Princess Alexander Hospital and Queensland University of Technology, Brisbane, Australia is the founding chair and president of BTOG. Dr Sanjay Popat (left), Consultant Medical Oncologist from the Royal Marsden Hospital, London took over the chair role in January 2013 (following BTOG 2013). Page 1 of 6

2 Education Programme of Events 13 th Annual BTOG Conference 2015 BTOG th to 30 th January 2015, Dublin BTOG 2015 attracted renowned speakers and chairs from the UK, Ireland, Europe, Australia, USA and Canada. The conference updated attendees on state of the art management of lung cancer and mesothelioma, increased understanding on the nature of clinical practice and research and facilitated networking for the development of new national and international clinical research studies in lung cancer and mesothelioma. Each year the British Thoracic Oncology Group (BTOG) gives a lifetime achievement award to an individual who in the steering committee s opinion has made a significant contribution to the management of thoracic malignancies in the UK and Ireland and this year this was presented to Dr Fergus Macbeth. BTOG 2015 was awarded 13 CPD Credits by the Royal Colleges of Physicians of the United Kingdom and 13 ESMO-MORA points category 1 by European Society for Medical Oncology (3 Wednesday and 6 Thursday and 4 Friday). The Royal College of Surgeons of England also awarded up to 10 points for Thursday and Friday. BTOG 2015 attracted 723 attendees. BTOG 2015 included 8 sponsored satellite meetings on Wednesday, Thursday and Friday and BTOG also held specialist symposia on Wednesday on the subjects of Translational Research, Respiratory Medicine and Radiotherapy Training BTOG Attendees Year Feedback from BTOG 2015 Very good, well organised conference. Excellent discussion on topical areas surrounding thoracic medicine and surgery - particularly focus on ongoing research helpful and inspiring. Sessions ran to time and discussion encouraged. Wonderful conference. I thoroughly enjoyed all of the sessions, with a fantastic mix of topics ranging from basic science to surgery. The question and answer part of the talks were also very informative and useful. Superb mix of speakers and topics. The conference was excellent for networking and enhancing your clinical skills and knowledge. I attend BTOG most years and always learn a lot from an enjoyable meeting. I think the standard of talks was better than ever this year and the structure of the whole event had clearly been thought through carefully. Page 2 of 6

3 BTOG Thoracic Oncology Course th and 13 th May 2014 Leicester The course is aimed at trainees and those entering the thoracic oncology speciality and all members of the MDT. The course was awarded 9 CPD credits from the Royal College of Phycians. Attendance totalled 75. Feedback from BTOG Course 2014 Very informative 2 days, very well organised. Group sessions allow time for interaction/ questions. Really good/refreshing to go to a course which concentrates on practical, relevant day to day practice rather than aspirational future potential treatments. I am new to oncology and found the course very informative and useful. Very informative course, well organised, focussed on daily clinical practice. I really enjoyed the course, it was very relevant to my practice. The presenters were very receptive to questions. Managing Mesothelioma in the UK Meeting in collaboration with Mesothelioma UK 12 th September 2014 London The study day was awarded 5 CPD credits from the Royal College of Physicians. Attendance totalled 119. Feedback from Mesothelioma Meeting Excellent, interactive meeting. Well organised and structured, hotel location easy to find, quality of catering very high. Excellent, well done. Relevant and useful. Liked the trials roundup. Impressive speaker line-up. Good range of speakers. Thank you for the hard work put in to organising. The speakers were all fantastic and definitely gave us all something to think about. Very informative and an eye opener into research into mesothelioma. Very optimistic about the long term development in mesothelioma. Publications Supplement to Lung Cancer journal published by Elsevier BTOG 2015 posters Reference: Lung Cancer 87 Suppl. 1 (2015) ISSN Page 3 of 6

4 A Practical Guide to Lung Cancer Nutritional Care published in January The BTOG steering committee was given the opportunity to comment on the draft guide and the final guide was endorsed by BTOG. BTS Guideline for the investigation and management of Pulmonary Nodules The BTOG steering committee was given the opportunity to comment on the draft guideline (to be published). Collaboration British Thoracic Society BTOG 2015 was held in collaboration with the British Thoracic Society, the European Thoracic Oncology Platform (ETOP), International Association for the Study of Lung Cancer (IASLC), Mesothelioma UK and National Lung Cancer Forum for Nurses (NLCFN). Collaborative sessions BTOG 2015 included the BTOG/British Thoracic Society (BTS)/ NCRI session, the BTOG/SCTS session and BTOG/NCRI subgroups workshops and BTOG/NLCFN workshop. Page 4 of 6

5 Representation BTOG has gained recognition as an appropriate body to review NICE submissions for new drug therapies for thoracic malignancies. Commentator: Pemetrexed for maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer [ID489] Crizotinib for the treatment of previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene [ID499] Afatinib for treating epidermal growth factor receptor mutation positive locally advanced or metastatic non-small cell lung cancer [ID556] Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed following prior chemotherapy (Review of TA162 and TA175) [ID620] Lung cancer (non-small cell, anaplastic lymphoma kinase positive, metastatic) - LDK378 (post chemotherapy) ID729 BTOG sent a written complaint to the Chair of the Cancer Drugs Fund (CDF) in February 2015 in relation to the decision to withdraw access to pemetrexed through the CDF. BTOG considered that withdrawal of maintenance pemetrexed from the CDF would be a backward step for NSCLC patients in England and would have a direct and negative impact on survival and outcomes. National Lung Cancer Audit Executive The BTOG steering committee is represented on this group by Dr Clive Mulatero (BTOG was invited to join the Executive January 2015). European Thoracic Oncology Platform (ETOP) BTOG is a member group of ETOP and BTOG President Ken O Byrne and BTOG steering committee member Keith Kerr are both members of the ETOP foundation council. The interest in promoting and improving collaboration in clinical and translational research in lung cancer and mesothelioma in Europe prompted investigators representing collaborative study groups and institutions concerned with thoracic malignancies to explore new ways of working together. Out of this discussion the European Thoracic Oncology Platform was founded in International Mesothelioma Interest Group 2016 Local Organising Committee BTOG is represented on this committee by Dr Sanjay Popat. Page 5 of 6

6 Steering Committee The steering committee met 4 times during this year April 2014, June 2014, October 2014 and January Please refer to Appendix A for list of steering committee members during this year. Website: BTOG Membership During this year membership was free of charge and there were >2,000 members. BTOG 2015 registrants (excluding industry) were given honorary membership of BTOG for 1 year from 1 January 2015 to 31 December The benefits of BTOG membership include:- access to the BTOG website ( member area including the document library (including presentations from the annual conference and study days subject to speaker permissions) notification of BTOG annual conference and study days chance to attend BTOG study days that, subject to sponsorship, are offered free of charge for health care professionals involved in thoracic oncology and travel bursaries are also available for travel within the UK and Ireland notification of thoracic oncology conferences/study days/other events circulation of thoracic oncology research and other news related to lung cancer and mesothelioma participation in research (questionnaires, surveys) The British Thoracic Oncology Group Charity (BTOG Charity) During this year Dawn Mckinley, BTOG Operational Manager and steering committee members, John Edwards and Mick Peake have continued to work relating to the setting up of the BTOG Charity. This will be completed during Page 6 of 6

Mesothelioma Priority Setting Partnership. PROTOCOL November 2013

Mesothelioma Priority Setting Partnership. PROTOCOL November 2013 Mesothelioma Priority Setting Partnership PROTOCOL November 2013 Purpose The purpose of this protocol is to set out the aims, objectives and commitments of the Mesothelioma Priority Setting Partnership

More information

THORACIC ONCOLOGY MULTIDISCIPLINARY TEAM MEETINGS: OPERATIONAL POLICY

THORACIC ONCOLOGY MULTIDISCIPLINARY TEAM MEETINGS: OPERATIONAL POLICY THORACIC ONCOLOGY MULTIDISCIPLINARY TEAM MEETINGS: OPERATIONAL POLICY EXECUTIVE SUMMARY 1. All patients in Lothian with thoracic malignancies should be discussed at designated times in pathway (see App

More information

The following information is only meant for people who have been diagnosed with advanced non-small cell

The following information is only meant for people who have been diagnosed with advanced non-small cell Important information for people with advanced non-small cell lung cancer The following information is only meant for people who have been diagnosed with advanced non-small cell lung cancer (NSCLC). NSCLC

More information

Lung Cancer & Mesothelioma 2011-2015

Lung Cancer & Mesothelioma 2011-2015 Lung Cancer & Mesothelioma 2011-2015 Annex G Mesothelioma 1. The vision for mesothelioma services is set out in the Mesothelioma Framework issued by DH on 26 February 2007 (supported by the British Thoracic

More information

ELCC 2015 Industry Satellite Symposium The Treatment Roadmap for Squamous NSCLC. Thursday 16th April 2015 13:10 14:20 Room C

ELCC 2015 Industry Satellite Symposium The Treatment Roadmap for Squamous NSCLC. Thursday 16th April 2015 13:10 14:20 Room C ELCC 2015 Industry Satellite Symposium The Treatment Roadmap for Squamous NSCLC Thursday 16th April 2015 13:10 14:20 Room C 1 Contents Programme.... 2 Welcome message.... 3 Faculty biographies.... 4 Symposium

More information

International Symposium on Malignant Pleural Mesothelioma

International Symposium on Malignant Pleural Mesothelioma International Symposium on Malignant Pleural Mesothelioma LONDON 2015 Friday 6th & Saturday 7th November 2015 Jumeirah Carlton Tower Hotel Cadogan Place Knightsbridge London SW1X 9PY United Kingdom Dear

More information

What is Mesothelioma? Mesothelioma is a cancer of the lining of the lung or the abdomen caused by asbestos.

What is Mesothelioma? Mesothelioma is a cancer of the lining of the lung or the abdomen caused by asbestos. 1 Report for: Health and Wellbeing Scrutiny Commission Meeting Date: 29 th October 2015 Subject: Mesothelioma UK Charitable Trust From: Ghislaine Boyd, Business Development Manager, Mesothelioma UK Charitable

More information

The East Midlands Mesothelioma Multi-disciplinary Team (MDT) Cancer Services Information for Patients

The East Midlands Mesothelioma Multi-disciplinary Team (MDT) Cancer Services Information for Patients The East Midlands Mesothelioma Multi-disciplinary Team (MDT) Cancer Services Information for Patients i Introduction The team of health professionals looking after you is known as the multidisciplinary

More information

Statewide Respiratory Clinical Network

Statewide Respiratory Clinical Network Statewide Respiratory Clinical Network Steering Committee Terms of Reference May 2012 Table of Contents 1. Purpose... 3 2. Principal Functions... 3 3. Reporting Responsibilities... 4 4. Steering Committee...

More information

REFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) GSK1572932A (NON-SMALL CELL LUNG CANCER) - Executive Summary GSK1572932A (MAGE-A3): Key Metrics in NSCLC Markets

More information

Lung Cancer and Pleural Mesothelioma: Cleveland Clinic Multidisciplinary Approaches to Care

Lung Cancer and Pleural Mesothelioma: Cleveland Clinic Multidisciplinary Approaches to Care Lung Cancer and Pleural Mesothelioma: Cleveland Clinic Multidisciplinary Approaches to Care Saturday, April 27, 2013 Cleveland Marriott Downtown at Key Center 127 Public Square Cleveland, Ohio Learning

More information

Wednesday 27 th January 2016 BTOG Parallel Symposia 11:00 to 14:30 Translational Research Radiotherapy Training Respiratory Medicine Radiology

Wednesday 27 th January 2016 BTOG Parallel Symposia 11:00 to 14:30 Translational Research Radiotherapy Training Respiratory Medicine Radiology 14 th Annual BTOG Conference 2016 Venue: Doubletree by Hilton Hotel Burlington Road, Dublin Wednesday 27 th to Friday 29 th January 2016 Continuing Professional Development Accreditation will be applied

More information

Chapter 7: Lung Cancer

Chapter 7: Lung Cancer Chapter 7: Lung Cancer Contents Chapter 7: Lung Cancer... 1 Small Cell... 2 Good PS + Limited stage... 2 Cisplatin/etoposide... 2 Concurrent chemotherapy + XRT... 2 Good / Intermediate PS... 2 Carboplatin

More information

How treatment is planned Giving your consent The benefits and disadvantages of treatment Second opinion

How treatment is planned Giving your consent The benefits and disadvantages of treatment Second opinion Treatment overview for lung cancer This information is an extract from the booklet Understanding lung cancer. You may find the full booklet helpful. We can send you a free copy see page 5. Contents How

More information

Lung Cancer Consultant Outcomes Publication

Lung Cancer Consultant Outcomes Publication Lung Cancer Consultant Outcomes Publication Introduction This report describes the outcomes of individual consultant thoracic and cardiothoracic surgeons who carry out surgery for lung cancer. It has been

More information

About chemotherapy for lung cancer

About chemotherapy for lung cancer About chemotherapy for lung cancer This information is about chemotherapy for lung cancer. There are sections on What is chemotherapy? Chemotherapy for small cell lung cancer Chemotherapy for non-small

More information

Advances in Lung Cancer: A Multidisciplinary Approach

Advances in Lung Cancer: A Multidisciplinary Approach Advances in Lung Cancer: A Multidisciplinary Approach Saturday, April 25, 2015 127 Public Square Cleveland, Ohio Learning Objectives About the Course This one-day course will provide a topical, clinically

More information

Mesothelioma in the UK

Mesothelioma in the UK Mesothelioma in the UK Liz Darlison Mesothelioma UK The National Macmillan Mesothelioma Resource Centre June 2010 Mesothelioma Applied Research Foundation - 2010 www.curemeso.org Contents Size of Mesothelioma

More information

Consent for Systemic Anti Cancer Therapy (SACT)

Consent for Systemic Anti Cancer Therapy (SACT) Consent for Systemic Anti Cancer Therapy (SACT) Guidance issued by the National Chemotherapy Board May 2016 Supported by: Contents National Chemotherapy Board 1. Introduction 1.1. Purpose of the guidance

More information

Breakthrough Lung Cancer Treatment Approved Webcast September 9, 2011 Renato Martins, M.D., M.P.H. Introduction

Breakthrough Lung Cancer Treatment Approved Webcast September 9, 2011 Renato Martins, M.D., M.P.H. Introduction Breakthrough Lung Cancer Treatment Approved Webcast September 9, 2011 Renato Martins, M.D., M.P.H. Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle Cancer

More information

National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007

National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007 Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.

More information

Erlotinib for the treatment of non-small cell lung cancer. Report from the Decision Support Unit in response to additional data submitted by Roche

Erlotinib for the treatment of non-small cell lung cancer. Report from the Decision Support Unit in response to additional data submitted by Roche Erlotinib for the treatment of non-small cell lung cancer Report from the Decision Support Unit in response to additional data submitted by Roche 10 th January 2008 Part 1: A Sutton. Critique of the network

More information

GOLNIK 17/06/10 COURSE ON LUNG CANCER AND MESOTHELIOMA. 17-18 June 2010 Golnik, Slovenia. Chair: T. Cufer, SI - G.L. Ceresoli, IT

GOLNIK 17/06/10 COURSE ON LUNG CANCER AND MESOTHELIOMA. 17-18 June 2010 Golnik, Slovenia. Chair: T. Cufer, SI - G.L. Ceresoli, IT ESO ADVANCED COURSES, SEMINARS AND SYMPOSIA GOLNIK 17/06/10 COURSE ON LUNG CANCER AND MESOTHELIOMA 17-18 June 2010 Golnik, Slovenia Chair: T. Cufer, SI - G.L. Ceresoli, IT AIM OF THE COURSE The incidence

More information

How do I find the best place to get treatment for my lymphoma?

How do I find the best place to get treatment for my lymphoma? Produced November 2010 Next revision due November 2012 How do I find the best place to get treatment for my lymphoma? Introduction Fortunately this is not a question that patients with cancers of the blood

More information

The Dream MDT for lung cancer: Delivering high quality lung cancer care and outcomes. UK Lung Cancer Coalition November 2012

The Dream MDT for lung cancer: Delivering high quality lung cancer care and outcomes. UK Lung Cancer Coalition November 2012 The Dream MDT for lung cancer: Delivering high quality lung cancer care and outcomes 1 UK Lung Cancer Coalition November 2012 November 2012 The Dream MDT for lung cancer Contents page Introduction 2 The

More information

Oxford Lung Cancer and Mesothelioma Multi- Disciplinary Team (MDT)

Oxford Lung Cancer and Mesothelioma Multi- Disciplinary Team (MDT) Oxford University Hospitals NHS Trust Oxford Lung Cancer and Mesothelioma Multi- Disciplinary Team (MDT) This information leaflet explains the role of the Multi-Disciplinary Team and Specialist Nursing

More information

Treatment of colon cancer

Treatment of colon cancer Treatment of colon cancer This information is an extract from the booklet, Understanding colon cancer. You may find the full booklet helpful. We can send you a copy free see page 5. Contents How treatment

More information

University College Hospital. The lung cancer multidisciplinary team. Information for patients and carers

University College Hospital. The lung cancer multidisciplinary team. Information for patients and carers University College Hospital The lung cancer multidisciplinary team Information for patients and carers 2 If you would like this document in another language or format, or require the services of an interpreter,

More information

GRANT APPLICATION FORM: ORGANISING AN ESO EDUCATIONAL EVENT

GRANT APPLICATION FORM: ORGANISING AN ESO EDUCATIONAL EVENT GRANT APPLICATION FORM: ORGANISING AN ESO EDUCATIONAL EVENT 1) TOPIC OF THE EVENT MALIGNANT PLEURAL DISEASE 2) SUGGESTED TITLE : Approach to Pleural Cancer: State-of-the-Art 3) TYPE OF EVENT Course Native

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium pemetrexed 500mg infusion (Alimta ) No. (192/05) Eli Lilly 8 July 2005 The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS

More information

Annual General Meeting of the. Faculty of Clinical Health Psychology. Agenda

Annual General Meeting of the. Faculty of Clinical Health Psychology. Agenda Faculty of Clinical Health Psychology Annual General Meeting of the Faculty of Clinical Health Psychology Agenda BPS London Office Thursday 19 February 2015 30 Tabernacle Street 12.30pm London EC2A 4UE

More information

DECISION AND SUMMARY OF RATIONALE

DECISION AND SUMMARY OF RATIONALE DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Crizotinib as 2nd line treatment for patients with anaplastic lymphoma kinase (ALK) positive lung cancer Score The application

More information

Lung Cancer in 2015: A Multidisciplinary Update

Lung Cancer in 2015: A Multidisciplinary Update Lung Cancer in 2015: A Multidisciplinary Update Invited Guest Faculty: Toronto General Hospital Toronto, Canada Saturday April 18, 2015 7:00 am-4:30 pm Westin Pasadena 191 N. Los Robles Avenue Pasadena,

More information

National Institute for Health and Clinical Excellence

National Institute for Health and Clinical Excellence Comment 1: the draft remit Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer Table of responses to consultee and commentator comments on the draft scope

More information

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness Department of Veterans Affairs Health Services Research & Development Service Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness

More information

Salisbury Lung Cancer Service (1 of 5)

Salisbury Lung Cancer Service (1 of 5) Salisbury Lung Cancer Service (1 of 5) i If you need this information in another language or medium (audio, large print, etc) please contact Customer Care on 0800 374 208 email: customercare@ salisbury.nhs.uk.

More information

GIORGIO VITTORIO SCAGLIOTTI, M.D. CURRICULUM VITAE

GIORGIO VITTORIO SCAGLIOTTI, M.D. CURRICULUM VITAE GIORGIO VITTORIO SCAGLIOTTI, M.D. CURRICULUM VITAE Personal Information Date of birth July 2, 1953 Place of birth Torino, Italy Office address Department of Oncology S. Luigi Gonzaga Hospital, Oncology

More information

London Cancer Annual Engagement Event: Unacceptable Lung Cancer Outcome Variation: Wednesday 3rd June 2015

London Cancer Annual Engagement Event: Unacceptable Lung Cancer Outcome Variation: Wednesday 3rd June 2015 London Cancer Annual Engagement Event: Unacceptable Lung Cancer Outcome Variation: Wednesday 3rd June 2015 Sam Janes BSc MBBS FRCP MSc PhD Vice-Chair of the Lung Cancer CRG NHS England London Cancer Lung

More information

2011 ATS International Conference May 13-18, 2011 Denver, Colorado CME POST-TEST QUESTIONAIRE

2011 ATS International Conference May 13-18, 2011 Denver, Colorado CME POST-TEST QUESTIONAIRE 2011 ATS International Conference May 13-18, 2011 Denver, Colorado CME POST-TEST QUESTIONAIRE Please fill your post-test answers in on this page and fax it back to the ATS Education Unit, ATTN: Elizabeth

More information

TARGET YOUR FUTURE RADIATION ONCOLOGY

TARGET YOUR FUTURE RADIATION ONCOLOGY TARGET YOUR FUTURE RADIATION ONCOLOGY A Career in Radiation Oncology YOUR CHOICE SAVE LIVES Take the first step towards a career in Radiation Oncology Visit www.acareerinradiationoncology.com.au What is

More information

Health Service Circular

Health Service Circular Health Service Circular Series Number: HSC 2002/009 Issue Date: 04 July 2002 Review Date: 04 July 2005 Category: Public Health Status: Action sets out a specific action on the part of the recipient with

More information

Division of Cancer Surgery Information Guide

Division of Cancer Surgery Information Guide Division of Cancer Surgery Information Guide Professor Sandy Heriot Director - Division Cancer Surgery Professor Michael Henderson Deputy Director Division Cancer Surgery Executive Sponsor Education and

More information

NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10

NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10 Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage

More information

REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM

REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM Valerie Van Damme, Isabelle Wauters, Johan Vansteenkiste Univ. Hospital Leuven and Leuven Lung Cancer Group Introduction Perspectives in Lung Cancer (PILC)

More information

NICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.

NICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic. bring together all NICE guidance, quality standards and other NICE information on a specific topic. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published.

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer

More information

Full name/ Title of Medical Qualifications Eligible for Conditional Registration. American Board of Obstetrics and Gynaecology

Full name/ Title of Medical Qualifications Eligible for Conditional Registration. American Board of Obstetrics and Gynaecology Conferred by s in the United States of America: Board Cert (Anaesthesiology) Board Cert (Anatomic Pathology) Board Cert (Cardiology) Board Cert (Cardiovascular Disease) Board Cert (Clinical Pathology)

More information

Ask Us About Clinical Trials

Ask Us About Clinical Trials Ask Us About Clinical Trials Clinical Trials and You. Our specialists and researchers are at the forefront of their fields and are leading the way in developing new therapies and procedures for diagnosing

More information

Proposal for Tyrosine Kinase Inhibitors for Non Small Cell Lung Cancer

Proposal for Tyrosine Kinase Inhibitors for Non Small Cell Lung Cancer 31 May 2012 Proposal for Tyrosine Kinase Inhibitors for Non Small Cell Lung Cancer PHARMAC is seeking feedback on a proposal to: fund gefitinib (Iressa) as a first line treatment for patients with locally

More information

Dr. Geoff Cuvelier. Pediatric Oncologist MD FRCPC

Dr. Geoff Cuvelier. Pediatric Oncologist MD FRCPC Dr. Geoff Cuvelier MD FRCPC Pediatric Oncologist Dr. Cuvelier is a graduate of the Faculty of Medicine, University of Manitoba, and received undergraduate degrees in microbiology and sociology from the

More information

targeted therapy a guide for the patient

targeted therapy a guide for the patient targeted therapy FOR LUNG CANCER a guide for the patient TABLE OF CONTENTS lung cancer basics... 2-3 Gene changes... 4-5 Testing... 7-8 Targeted therapy... 9-11 Drugs Targeting EGFR... 12 Drugs Targeting

More information

Teaming Up Against Sarcoma

Teaming Up Against Sarcoma Teaming Up Against Sarcoma Recorded on: April 4, 2013 Darin Davidson, MD, MHSc, FRCSC Assistant Professor, Department of Orthopaedics and Sports Medicine University of Washington School of Medicine Robin

More information

Lung SSG 6 th May 2015 Research

Lung SSG 6 th May 2015 Research Lung SSG 6 th May 2015 Research Wendy Cook, Research Delivery Manager dd/mm/yyyy Delivering clinical research to make patients, and the NHS, better South West Peninsula CRN Hospital Yeovil District Hospital

More information

SAKK Lung Cancer Group. Current activities and future projects

SAKK Lung Cancer Group. Current activities and future projects SAKK Lung Cancer Group Current activities and future projects SAKK Lung Cancer Group Open group of physicians interested in lung cancer Mostly Medical Oncologists, but also Thoracic Surgeons Radiation

More information

A guide to prostate cancer clinical trials

A guide to prostate cancer clinical trials 1 A guide to prostate cancer clinical trials In this fact sheet: What is a clinical trial? Why are trials done? What are trials looking into at the moment? How are clinical trials done? Should I take part

More information

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in

More information

Treatment Algorithms for the Management of Lung Cancer in NSW Guide for Clinicians

Treatment Algorithms for the Management of Lung Cancer in NSW Guide for Clinicians Treatment Algorithms for the Management of Lung Cancer in NSW Guide for Clinicians Background The Cancer Institute New South Wales Oncology Group Lung (NSWOG Lung) identified the need for the development

More information

Targeted Therapies in Lung Cancer

Targeted Therapies in Lung Cancer Targeted Therapies in Lung Cancer I Edited by: Simona Carnio Thoracic Oncology Division - St Luigi Hospital Orbassano (TO) - Italy Silvia Novello Department of Oncology - University of Torino - Italy Why

More information

PATIENT INFORMATION SHEET

PATIENT INFORMATION SHEET PATIENT INFORMATION SHEET Surgical and large bore pleural procedures in Malignant pleural Mesothelioma And Radiotherapy Trial (SMART trial) Stoke Mandeville Hospital Mandeville Road Aylesbury Buckinghamshire

More information

Lung Cancer Multidisciplinary Meeting Toolkit. National Lung Cancer Working Group

Lung Cancer Multidisciplinary Meeting Toolkit. National Lung Cancer Working Group Lung Cancer Multidisciplinary Meeting Toolkit National Lung Cancer Working Group September 2014 Contents Introduction 1 Multidisciplinary meetings 1 Toolkit for implementing high-quality lung cancer MDMs

More information

Therapeutic Goods Administration Orphan Drugs Program: Discussion paper

Therapeutic Goods Administration Orphan Drugs Program: Discussion paper Therapeutic Goods Administration Orphan Drugs Program: Discussion paper Submission from the Clinical Oncology Society of Australia and Cancer Council Australia March 2015 The Clinical Oncology Society

More information

Memorandum. The Faculty of Public Health of the Royal Colleges of the United Kingdom. (Registered Charity No 263894)

Memorandum. The Faculty of Public Health of the Royal Colleges of the United Kingdom. (Registered Charity No 263894) Memorandum The Faculty of Public Health of the Royal Colleges of the United Kingdom (Registered Charity No 263894) History and role The Faculty of Public Health (FPH) was established in 1972 as a joint

More information

Leading cancer treatments and improving outcomes for patients: Our 20:20 Vision

Leading cancer treatments and improving outcomes for patients: Our 20:20 Vision Leading cancer treatments and improving outcomes for patients: Our Why? Our patients will always come first and no matter what our vision is for the years ahead, this ethos of will always remain the same.

More information

A developmental framework for pharmacists progressing to advanced levels of practice

A developmental framework for pharmacists progressing to advanced levels of practice ACLF Advanced to Consultant level Framework A developmental framework for pharmacists progressing to advanced levels of practice Version 2009(a) CoDEG www.codeg.org ADVANCED AND CONSULTANT LEVEL COMPETENCY

More information

POLICY A. INDICATIONS

POLICY A. INDICATIONS Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below

More information

4) GENERAL PRINCIPLES

4) GENERAL PRINCIPLES 1) NAME Australia & New Zealand - Lung Cancer Nurses Forum (ANZ-LCNF) TERMS OF REFERENCE The group shall be known as the Australia & New Zealand - Lung Cancer Nurses Forum (ANZ-LCNF) Statement of Purpose:

More information

SCR Expert Advisory Committee

SCR Expert Advisory Committee SCR Expert Advisory Committee Terms of Reference Judith Brodie, Chair August 2015 1 Copyright 2015, Health and Social Care Information Centre. Contents Contents 2 1. Background and Strategic Justification

More information

Non-Small Cell Lung Cancer Therapies

Non-Small Cell Lung Cancer Therapies Non-Small Cell Lung Cancer Therapies Guest Expert: Roy, MD, PhD Assistant Professor of Therapeutic Radiology Scott, MD Assistant Professor of Medical Oncology www.wnpr.org www.yalecancercenter.org Welcome

More information

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness Investigators: Paul G. Shekelle, MD, PhD, Director Alicia R. Maher, MD Clinical

More information

Treatment Guide Lung Cancer Management

Treatment Guide Lung Cancer Management Treatment Guide Lung Cancer Management The Chest Cancer Center at Cleveland Clinic, which includes specialists from the Respiratory Institute, Taussig Cancer Institute and Miller Family Heart & Vascular

More information

Summary of treatment benefits

Summary of treatment benefits Risk Management Plan PEMETREXED Powder for concentrate for Solution for infusion Pemetrexed is also indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non small cell

More information

Skill Levels for Delivering High Quality Asthma and COPD Respiratory Care by Nurses in Primary Care

Skill Levels for Delivering High Quality Asthma and COPD Respiratory Care by Nurses in Primary Care Skill Levels for Delivering High Quality Asthma and COPD Respiratory Care by Nurses in Primary Care September 2007 Revised December 2009, April 2014 Author: Ruth McArthur In conjunction with the PCRS-UK

More information

PATIENT INFORMATION SHEET Study name: CT morphology of lung parenchyma pre and post bariatric surgery: correlation with pulmonary function.

PATIENT INFORMATION SHEET Study name: CT morphology of lung parenchyma pre and post bariatric surgery: correlation with pulmonary function. Version 2. 8.09.2011 Hammersmith Hospital Du Cane Rd London W12 0HS Tel: 020 8383 1000 www.imperial.nhs.uk PATIENT INFORMATION SHEET Study name: CT morphology of lung parenchyma pre and post bariatric

More information

Manchester Pharmacy School. www.manchester.ac.uk/pharmacy

Manchester Pharmacy School. www.manchester.ac.uk/pharmacy Manchester Pharmacy School Postgraduate study from Continuous Professional Development (CPD), Certificate, Diploma to Masters (MSc) with flexible, modular learning. The University of Manchester has a proud

More information

National Macmillan Mesothelioma Resource Centre. Bulletin April 2008 MESOTHELIOMA UK UPDATE

National Macmillan Mesothelioma Resource Centre. Bulletin April 2008 MESOTHELIOMA UK UPDATE Direct Line 0116 256 3739 Fax 0116 250 2810 Email: mesothelioma.uk@uhl-tr.nhs.uk Helpline 0800 169 2409 Website www.mesothelioma.uk.com MESOTHELIOMA UK National Macmillan Mesothelioma Resource Centre Bulletin

More information

Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center

Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.

More information

MEDICAL ONCOLOGY (1) INTRODUCTION (2) MEDICAL ONCOLOGY PROGRAMS ACROSS CANADA (3) UNIVERSITY OF MANITOBA PROGRAM

MEDICAL ONCOLOGY (1) INTRODUCTION (2) MEDICAL ONCOLOGY PROGRAMS ACROSS CANADA (3) UNIVERSITY OF MANITOBA PROGRAM MEDICAL ONCOLOGY (1) INTRODUCTION Medical oncologists are physicians who have specialized in the assessment and management of patients with cancer. They are trained to use systemic drugs in the treatment

More information

Appendix 1 Current list of approved qualifications for Locum Tenens registration

Appendix 1 Current list of approved qualifications for Locum Tenens registration Appendix 1 Current list of approved qualifications for Locum Tenens registration Anaesthesia Fellowship of the Australian and New Zealand College of Anaesthetists Fellowship of the Faculty of Anaesthetists,

More information

Treatment options for recurrent ovarian cancer

Treatment options for recurrent ovarian cancer Treatment options for recurrent ovarian cancer There are a number of treatment options for women with recurrent ovarian cancer. Chemotherapy is the treatment most commonly offered and on occasion, surgery

More information

The Bologna Process implications for UK and Irish medical schools

The Bologna Process implications for UK and Irish medical schools The Bologna Process implications for UK and Irish medical schools Professor Allan Cumming University of Edinburgh Leader, Tuning Project for Medicine Professor Fons Plaschaert University of Nimigjen Coordinator,

More information

Patient and Family Myeloma Infoday

Patient and Family Myeloma Infoday Patient and Family Myeloma Infoday Cardiff Saturday 9 November 2013 Cardiff Village Hotel www.myeloma.org.uk/infodays #mukinfodays Dear Attendee Welcome to our Cardiff Patient and Family Myeloma Infoday.

More information

National Lung Cancer Audit Report

National Lung Cancer Audit Report National Lung Cancer Audit Report 2013 Report for the audit period 2012 Copyright 2013, Health and Social Care Information Centre, National Lung Cancer Audit. All rights reserved. 1 Prepared in partnership

More information

Which treatment for advanced lung cancer

Which treatment for advanced lung cancer Which treatment for advanced lung cancer This information tells you about the treatments for advanced lung cancer. Chemotherapy and radiotherapy can both be used to treat advanced lung cancer. They can

More information

Improving healthcare for people with long-term conditions

Improving healthcare for people with long-term conditions Improving healthcare for people with long-term conditions UWe-book: Number Two 1 Health and Well-being At UWE our research and development is real and dynamic, identifying problems and providing solutions

More information

Systemic Therapy for Stage IV Non-Small Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

Systemic Therapy for Stage IV Non-Small Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Systemic Therapy for Stage IV Non-Small Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Introduction The purpose of this guideline update is to revise the 2011

More information

Emerging Drug List GEFITINIB

Emerging Drug List GEFITINIB Generic (Trade Name): Manufacturer: Gefitinib (Iressa ) formerly referred to as ZD1839 AstraZeneca NO. 52 JANUARY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence:

More information

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s

More information

The Characteristics of an Effective Multidisciplinary Team (MDT)

The Characteristics of an Effective Multidisciplinary Team (MDT) National Cancer Action Team The Characteristics of an Effective Multidisciplinary Team (MDT) February 2010 Contents Page Foreword The Characteristics of an Effective MDT Aim Introduction Categorisation

More information

30-31. Advancesincancer immunologyand immunotherapy. announcement. October2015. Royal Olympic Hotel Athens

30-31. Advancesincancer immunologyand immunotherapy. announcement. October2015. Royal Olympic Hotel Athens Advancesincancer immunologyand immunotherapy 30-31 October2015 Royal Olympic Hotel Athens announcement Organizer Hellenic Oncology Research Group (HORG) Symposium chairs N. Kentepozidis, A. Kotsakis, M.

More information

Professional Competence. Guidelines for Doctors

Professional Competence. Guidelines for Doctors Professional Competence Guidelines for Doctors Professional competence at a glance What doctors need to know Contact the postgraduate training body most relevant to your day-to-day practice and enrol in

More information

OVERVIEW OF IPTR AND NON-FORMULARY PROCESS IN THE ACUTE SECTOR

OVERVIEW OF IPTR AND NON-FORMULARY PROCESS IN THE ACUTE SECTOR 5.2: POLICY FOR THE MANAGEMENT OF INDIVIDUAL PATIENT TREATMENT REQUESTS IMPORTANT NOTE: This policy document is subject to review pending the introduction of the Peer Approval Clinical System which will

More information

Lung Cancer: More than meets the eye

Lung Cancer: More than meets the eye Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research

More information

Reconfiguration of Surgical, Accident and Emergency and Trauma Services in the UK

Reconfiguration of Surgical, Accident and Emergency and Trauma Services in the UK Reconfiguration of Surgical, Accident and Emergency and Trauma Services in the UK K Reconfiguration of Surgical, Accident and Emergency and Trauma Services in the UK Summary Our aim is to provide an excellent

More information

MARKETING & EXHIBITOR PROSPECTUS

MARKETING & EXHIBITOR PROSPECTUS MARKETING & EXHIBITOR PROSPECTUS May 26-29, 2016 Sawgrass Marriott, Ponte Vedra Beach (Jacksonville), Florida Our vision: Life free of diabetes and all its burdens. Our mission: To prevent and cure diabetes

More information

UNIVERSITY MEDICAL CENTRE PATIENT PARTICIPATION GROUP ANNUAL REPORT & ACTION PLAN 2012-13

UNIVERSITY MEDICAL CENTRE PATIENT PARTICIPATION GROUP ANNUAL REPORT & ACTION PLAN 2012-13 UNIVERSITY MEDICAL CENTRE PATIENT PARTICIPATION GROUP ANNUAL REPORT & ACTION PLAN 2012-13 Introduction & Recruitment of the Patient Participation Group Review on how and why the Patient group was established:

More information

A new predictive algorithm for aiding clinical decision-making in lung cancer

A new predictive algorithm for aiding clinical decision-making in lung cancer Better Care. Faster A new predictive algorithm for aiding clinical decision-making in lung cancer Y Kogan, I Sela, Y Kheiffetz, M Kleiman, Z Agur, Optimata Ltd., O Liran, N Peled, Sheba hospital, I Lazarev,

More information

Targeted Therapy What the Surgeon Needs to Know

Targeted Therapy What the Surgeon Needs to Know Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures

More information